Hepion Pharmaceuticals (HEPA) investor relations material

Executive summary

• Transitioned focus from drug development to medical diagnostics, licensing liver disease diagnostic assets from Cirna Diagnostics in February 2026, with upfront and milestone payments structured.

• Leadership changes included new employment agreements for the Executive Chairman and CEO in May 2026, and a new COO in August 2026.

• Accumulated deficit reached $248.2 million as of June 30, 2026, with no commercial revenue generated to date.

Financial highlights

• Net loss for Q2 2026 was $1.25 million, compared to $1.04 million in Q2 2025; net loss for the six months ended June 30, 2026 was $2.06 million, down from $7.15 million in the prior year period.

• General and administrative expenses increased by $0.2 million year-over-year for the quarter, mainly due to higher personnel costs.

• Research and development expenses decreased to $0.1 million for Q2 2026, reflecting lower activity post-asset acquisition.

• Cash balance as of June 30, 2026 was $1.6 million, down from $1.8 million at year-end 2025.

• Working capital stood at $1.4 million at quarter-end, compared to $2.8 million at December 31, 2025.

Outlook and guidance

• Management expects continued significant losses and negative cash flows, with no commercial products anticipated for several years, if at all.

• Additional capital will be required to fund ongoing operations and strategic initiatives.